A Dark Vector Cognition product

Item 1. FINANCIAL STATEMENTS

57K characters. Original on sec.gov ·

Item 1. FINANCIAL STATEMENTS

The 18 tables in Item 1. FINANCIAL STATEMENTS as one CSV, figures in aligned columns. For subscribers: paste your API key. One API call. Plans from $19 a month, see pricing.

Roper Technologies, Inc. and Subsidiaries

Condensed Consolidated Statements of Earnings (unaudited)

(in millions, except per share data)

Three months ended March 31,
20222021
Net revenues$1,526.6$1,376.1
Cost of sales496.5440.1
Gross profit1,030.1936.0
Selling, general and administrative expenses609.0561.4
Income from operations421.1374.6
Interest expense, net52.660.6
Other income (expense), net(1.9)27.1
Earnings before income taxes366.6341.1
Income taxes79.071.2
Net earnings from continuing operations287.6269.9
Earnings from discontinued operations, net of tax15.619.1
Gain on disposition of discontinued operations, net of tax1,717.3—
Net earnings from discontinued operations1,732.919.1
Net earnings$2,020.5$289.0
Net earnings per share from continuing operations:
Basic$2.72$2.57
Diluted$2.70$2.55
Net earnings per share from discontinued operations:
Basic$16.41$0.18
Diluted$16.24$0.18
Net earnings per share:
Basic$19.13$2.75
Diluted$18.94$2.73
Weighted average common shares outstanding:
Basic105.6105.0
Diluted106.7106.0

See accompanying notes to Condensed Consolidated Financial Statements.

Roper Technologies, Inc. and Subsidiaries

Condensed Consolidated Statements of Comprehensive Income (unaudited)

(in millions)

Three months ended March 31,
20222021
Net earnings$2,020.5$289.0
Other comprehensive income (loss), net of tax:
Foreign currency translation adjustments(22.9)14.6
Total other comprehensive income (loss), net of tax(22.9)14.6
Comprehensive income$1,997.6$303.6

See accompanying notes to Condensed Consolidated Financial Statements.

Roper Technologies, Inc. and Subsidiaries

Condensed Consolidated Balance Sheets (unaudited)

(in millions)

March 31, 2022December 31, 2021
ASSETS:
Cash and cash equivalents$3,237.5$351.5
Accounts receivable, net755.3839.4
Inventories, net202.7176.1
Income taxes receivable19.227.7
Unbilled receivables110.095.3
Other current assets160.9142.5
Current assets held for sale—788.6
Total current assets4,485.62,421.1
Property, plant and equipment, net98.9102.8
Goodwill14,094.914,094.5
Other intangible assets, net6,454.16,588.5
Deferred taxes101.4101.1
Other assets400.9405.9
Total assets$25,635.8$23,713.9
LIABILITIES AND STOCKHOLDERS' EQUITY:
Accounts payable$167.8$150.8
Accrued compensation208.2309.8
Deferred revenue1,120.31,130.2
Other accrued liabilities413.0440.7
Income taxes payable793.0132.0
Current portion of long-term debt, net799.5799.2
Current liabilities held for sale—159.1
Total current liabilities3,501.83,121.8
Long-term debt, net of current portion6,654.87,122.6
Deferred taxes1,476.11,479.5
Other liabilities451.2426.2
Total liabilities12,083.912,150.1
Commitments and contingencies (Note 10)
Common stock1.11.1
Additional paid-in capital2,363.92,307.8
Retained earnings11,410.49,455.6
Accumulated other comprehensive loss(206.0)(183.1)
Treasury stock(17.5)(17.6)
Total stockholders' equity13,551.911,563.8
Total liabilities and stockholders' equity$25,635.8$23,713.9

See accompanying notes to Condensed Consolidated Financial Statements.

Roper Technologies, Inc. and Subsidiaries

Condensed Consolidated Statements of Cash Flows (unaudited)

(in millions)

Three months ended March 31,
20222021
Cash flows from operating activities:
Net earnings from continuing operations$287.6$269.9
Adjustments to reconcile net earnings from continuing operations to cash flows from operating activities:
Depreciation and amortization of property, plant and equipment11.013.1
Amortization of intangible assets148.1146.3
Amortization of deferred financing costs3.13.4
Non-cash stock compensation35.931.6
Gain on sale of assets, net of tax—(21.6)
Income tax provision, excluding tax associated with gain on sale of assets79.065.7
Changes in operating assets and liabilities, net of acquired businesses:
Accounts receivable82.054.3
Unbilled receivables(15.4)(17.8)
Inventories(27.7)(2.1)
Accounts payable17.913.3
Other accrued liabilities(125.1)(59.0)
Deferred revenue29.460.9
Cash income taxes paid(27.4)(17.2)
Other, net(24.6)(14.9)
Cash provided by operating activities from continuing operations473.8525.9
Cash provided by operating activities from discontinued operations1.533.7
Cash provided by operating activities475.3559.6
Cash flows from (used in) investing activities:
Acquisitions of businesses, net of cash acquired(53.2)—
Capital expenditures(7.1)(7.1)
Capitalized software expenditures(7.5)(7.2)
Proceeds from sale of assets—27.1
Other, net—(0.1)
Cash (used in) provided by investing activities from continuing operations(67.8)12.7
Proceeds from disposition of discontinued operations3,006.2—
Cash used in investing activities from discontinued operations(0.2)(2.0)
Cash provided by investing activities2,938.210.7
Cash flows from (used in) financing activities:
Borrowings (payments) under revolving line of credit, net(470.0)(495.0)
Cash dividends to stockholders(65.3)(58.8)
Proceeds from stock-based compensation, net21.04.4
Treasury stock sales5.54.7
Other—(0.1)
Cash flows used in financing activities from continuing operations(508.8)(544.8)
Cash flows used in financing activities from discontinued operations(11.4)(0.4)
Cash flows used in financing activities(520.2)(545.2)
(Continued)

Roper Technologies, Inc. and Subsidiaries

Condensed Consolidated Statements of Cash Flows (unaudited) - Continued

(in millions)

Three months ended March 31,
20222021
Effect of foreign currency exchange rate changes on cash(7.3)(2.4)
Net increase in cash and cash equivalents2,886.022.7
Cash and cash equivalents, beginning of period351.5308.3
Cash and cash equivalents, end of period$3,237.5$331.0

See accompanying notes to Condensed Consolidated Financial Statements.

Roper Technologies, Inc. and Subsidiaries

Condensed Consolidated Statements of Changes in Stockholders’ Equity (unaudited)

(in millions)

Common stockAdditional paid-in capitalRetained earningsAccumulated other comprehensive lossTreasury stockTotal stockholders’ equity
Balances at December 31, 2021$1.1$2,307.8$9,455.6$(183.1)$(17.6)$11,563.8
Net earnings——2,020.5——2,020.5
Stock option exercises—38.7———38.7
Cash settlement of share-based awards in connection with disposition of discontinued operations—(11.1)———(11.1)
Treasury stock sold—5.4——0.15.5
Currency translation adjustments———(22.9)—(22.9)
Stock-based compensation—40.8———40.8
Restricted stock activity—(17.7)———(17.7)
Dividends declared ($0.62 per share)——(65.7)——(65.7)
Balances at March 31, 2022$1.1$2,363.9$11,410.4$(206.0)$(17.5)$13,551.9
Balances at December 31, 2020$1.1$2,097.5$8,546.2$(147.0)$(18.0)$10,479.8
Net earnings——289.0——289.0
Stock option exercises—19.2———19.2
Treasury stock sold—4.6——0.14.7
Currency translation adjustments———14.6—14.6
Stock-based compensation—32.4———32.4
Restricted stock activity—(14.8)———(14.8)
Dividends declared ($0.5625 per share)——(59.2)——(59.2)
Balances at March 31, 2021$1.1$2,138.9$8,776.0$(132.4)$(17.9)$10,765.7

See accompanying notes to Condensed Consolidated Financial Statements.

Roper Technologies, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements (unaudited)

All currency and share amounts are in millions, except per share data

1. Basis of Presentation

The accompanying Condensed Consolidated Financial Statements for the three months ended March 31, 2022 and 2021 are unaudited. In the opinion of management, the accompanying unaudited Condensed Consolidated Financial Statements reflect all adjustments, which include only normal recurring adjustments, necessary to state fairly the financial position, results of operations, comprehensive income and cash flows of Roper Technologies, Inc. and its subsidiaries (“Roper,” the “Company,” “we,” “our” or “us”) for all periods presented. The December 31, 2021 financial position data included herein was derived from the audited consolidated financial statements included in the Company’s 2021 Annual Report on Form 10-K (“Annual Report”) filed on February 22, 2022 with the Securities and Exchange Commission (“SEC”) but does not include all disclosures required by U.S. generally accepted accounting principles (“GAAP”).

Roper’s management has made estimates and assumptions relating to the reporting of assets and liabilities and the disclosure of contingent assets and liabilities to prepare these Condensed Consolidated Financial Statements in conformity with GAAP. Actual results could differ from those estimates.

During 2021, the Company signed definitive agreements to divest our TransCore, Zetec and CIVCO Radiotherapy businesses. As of March 31, 2022, Roper has completed all three divestitures. The financial results for these businesses are presented as discontinued operations for all periods presented. Unless otherwise noted, discussion within these notes to the Condensed Consolidated Financial Statements relate to continuing operations. Refer to Note 5 for additional information on discontinued operations.

The results of operations for the three months ended March 31, 2022 are not necessarily indicative of the results to be expected for the full year. You should read these unaudited Condensed Consolidated Financial Statements in conjunction with Roper’s audited consolidated financial statements and the notes thereto included in its Annual Report. Certain prior period amounts have been reclassified to conform to current period presentation.

2. Recent Accounting Pronouncements

The Financial Accounting Standards Board (“FASB”) establishes changes to accounting principles under GAAP in the form of accounting standards updates (“ASUs”) to the Accounting Standards Codification (“ASC”). The Company considers the applicability and impact of all ASUs. Any recent ASUs not listed were assessed and determined to be either not applicable or are expected to have an immaterial impact on the Company’s results of operations, financial position or cash flows.

3. Weighted Average Shares Outstanding

Basic earnings per share were calculated using net earnings and the weighted average number of shares of common stock outstanding during the respective period. Diluted earnings per share were calculated using net earnings and the weighted average number of shares of common stock and potential common stock outstanding during the respective period. Potentially dilutive common stock consisted of stock options based upon the trading price of Roper’s common stock. The effects of potential common stock were determined using the treasury stock method. Weighted average shares outstanding are shown below:

Three months ended March 31,
20222021
Basic shares outstanding105.6105.0
Effect of potential common stock:
Common stock awards1.11.0
Diluted shares outstanding106.7106.0

For the three months ended March 31, 2022, there were 0.840 outstanding stock options, respectively, that were not included in the determination of diluted earnings per share because doing so would have been antidilutive, as compared to 0.647 outstanding stock options that would have been antidilutive in the respective 2021 period.

4. Business Acquisitions and Disposition

On January 3, 2022, Roper acquired the outstanding membership interests of Horizon Lab Systems, LLC, a provider of laboratory information management systems in the toxicology, environmental, public health and agricultural markets for an aggregate purchase price of $49.8. This acquisition has been integrated into our Clinisys business and its results are reported in the Application Software reportable segment. The results of operations of the acquired business are included in Roper’s Condensed Consolidated Financial Statements since the date of acquisition. Pro forma results of operations and the revenue and net income subsequent to the acquisition date has not been presented because the effects of the acquisition were not material to our financial results.

The Company recorded $25.6 in goodwill and $23.3 of other identifiable intangibles in connection with this acquisition. The amortizable intangible assets include customer relationships of $20.9 (15.1 year weighted average useful life) and technology of $2.4 (5.3 year weighted average useful life).

Disposition

On March 17, 2021, Roper completed the sale of a minority investment in Sedaru, Inc. for $27.1. The pretax gain on the sale was $27.1, which is reported in “Other income (expense), net” in the Condensed Consolidated Statement of Earnings.

5. Discontinued Operations

During 2021, the Company signed definitive agreements to divest our TransCore, Zetec and CIVCO Radiotherapy businesses as described below.

  • On March 17, 2022, Roper closed on the divestiture of our TransCore business to an affiliate of Singapore Technologies Engineering Ltd., for approximately $2,680.0 in cash. The sale resulted in a pretax gain of $2,073.7 and income tax expense of $550.5, which are reported within “Gain on disposition of discontinued operations, net of tax” in the Condensed Consolidated Statements of Earnings. TransCore was previously included in the Network Software & Systems reportable segment.

  • On January 5, 2022, Roper closed on the divestiture of our Zetec business to Eddyfi NDT Inc. for approximately $350.0 in cash. The sale resulted in a pretax gain of $255.3 and income tax expense of $60.9, which are reported within “Gain on disposition of discontinued operations, net of tax” in the Condensed Consolidated Statements of Earnings. Zetec was previously included in the Process Technologies reportable segment.

  • On November 1, 2021, Roper closed the divestiture of our CIVCO Radiotherapy business to an affiliate of Blue Wolf Capital Partners LLC. CIVCO Radiotherapy business was previously included in the Measurement & Analytical Solutions reportable segment.

The Company concluded these disposal activities, in the aggregate, represented a strategic shift that will have a major effect on the Company’s operations and financial results. These divestitures significantly enhance our mix of high-margin, recurring revenue businesses and notably reduce our working capital requirements. Accordingly, the financial results of the TransCore, Zetec and CIVCO Radiotherapy businesses are presented in the Condensed Consolidated Financial Statements as discontinued operations for all periods presented. Current and non-current assets and liabilities of these businesses are presented in the

Condensed Consolidated Balance Sheet as assets and liabilities of discontinued operations classified as held for sale at December 31, 2021.

The following tables summarize the major classes of assets and liabilities related to the discontinued operations of the TransCore, Zetec and CIVCO Radiotherapy businesses, as reported in the Condensed Consolidated Balance Sheets at December 31, 2021:

Accounts receivable, net$74.7
Inventories, net47.8
Unbilled receivables158.2
Goodwill405.5
Other intangible assets, net31.0
Other current assets71.4
Current assets held for sale$788.6
Accounts payable$40.3
Accrued compensation27.0
Deferred taxes29.5
Other current liabilities62.3
Current liabilities held for sale$159.1

The following table summarizes the major classes of revenue and expenses constituting net income from discontinued operations attributable to the TransCore, Zetec and CIVCO Radiotherapy businesses:

Three Months Ended March 31,
20222021
Net revenues$100.4$152.5
Cost of sales71.294.7
Gross profit29.257.8
Selling, general and administrative expenses (1)19.931.9
Income from operations9.325.9
Other income (expense), net0.1(0.1)
Earnings before income taxes (2)9.425.8
Income taxes(6.2)6.7
Earnings from discontinued operations, net of tax15.619.1
Gain on disposition of discontinued operations, net of tax1,717.3—
Net earnings from discontinued operations$1,732.9$19.1

(1) Includes stock-based compensation expense of $0.9 and $1.3 for the three months ended March 31, 2022 and 2021, respectively. In connection with the sale of TransCore and Zetec, we recognized expense of $4.5 associated with accelerated vesting of share-based awards. The charges associated with accelerated vesting were recorded as a component of “Gain on disposition of discontinued operations, net of tax” within the Condensed Consolidated Statements of Earnings.

(2) During the three months ended March 31, 2022, there was no depreciation of property, plant and equipment or amortization of intangible assets given the asset classification as held for sale during the period. During the three months ended March 31, 2021 depreciation and amortization was $1.9.

6. Stock Based Compensation

The Roper Technologies, Inc. 2021 Incentive Plan (“2021 Plan”) is a stock-based compensation plan used to grant incentive stock options, nonqualified stock options, restricted stock, stock appreciation rights or equivalent instruments to Roper’s employees, officers, directors and consultants.

The following table provides information regarding the Company’s stock-based compensation expense:

Three Months Ended March 31,
20222021
Stock-based compensation$35.9$31.6
Tax effect recognized in net earnings from continuing operations7.56.6

Stock Options - In the three months ended March 31, 2022, 0.365 options were granted with a weighted average fair value of $115.83 per option. During the same period in 2021, 0.498 options were granted with a weighted average fair value of $94.69 per option. All options were issued with an exercise price equal to the closing price of Roper’s common stock on the date of grant, as required by the 2021 Plan.

Roper records compensation expense for employee stock options based on the estimated fair value of the options on the date of grant using the Black-Scholes option-pricing model. Historical data is used to estimate the expected price volatility, the expected dividend yield, the expected option life and the expected forfeiture rate. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant for the estimated life of the option.

The following weighted average assumptions were used to estimate the fair value of options granted during current and prior year periods using the Black-Scholes option-pricing model:

Three months ended March 31,
20222021
Risk-free interest rate (%)2.050.94
Expected option life (years)5.635.61
Expected volatility (%)24.5225.16
Expected dividend yield (%)0.540.56

Cash received from option exercises for the three months ended March 31, 2022 and 2021 was $38.7 and $19.2, respectively.

Restricted Stock Grants - During the three months ended March 31, 2022, the Company granted 0.219 shares with a weighted average grant date fair value of $455.84 per restricted share. During the same period in 2021, the Company granted 0.207 shares with a weighted average grant date fair value of $404.14 per restricted share. All grants were issued at grant date fair value.

During the three months ended March 31, 2022, 0.116 restricted shares vested with a weighted average grant date fair value of $329.75 per restricted share and a weighted average vest date fair value of $457.31 per restricted share.

Employee Stock Purchase Plan - Roper’s employee stock purchase plan (“ESPP”) allows employees in the U.S. and Canada to designate up to 10% of eligible earnings to purchase Roper’s common stock at a 10% discount on the lower of the closing price of the stock on the first and last day of each quarterly offering period. Common stock sold to employees pursuant to the ESPP may be either treasury stock, stock purchased on the open market, or newly issued shares.

During the three months ended March 31, 2022 and 2021, participants in the ESPP purchased 0.013 and 0.013 shares of Roper’s common stock for total consideration of $5.5 and $4.7, respectively. All shares were purchased from Roper’s treasury shares.

7. Inventories

The components of inventory were as follows:

March 31, 2022December 31, 2021
Raw materials and supplies$131.5$112.7
Work in process36.030.2
Finished products72.169.3
Inventory reserves(36.9)(36.1)
Inventories, net$202.7$176.1

8. Goodwill and Other Intangible Assets

The carrying value of goodwill by segment was as follows:

Application SoftwareNetwork Software & SystemsMeasurement & Analytical SolutionsProcess TechnologiesTotal
Balances at December 31, 2021$8,889.3$3,797.0$1,160.6$247.6$14,094.5
Additions25.6———25.6
Other—(0.5)——(0.5)
Currency translation adjustments(6.6)(12.1)(5.0)(1.0)(24.7)
Balances at March 31, 2022$8,908.3$3,784.4$1,155.6$246.6$14,094.9

Other relates primarily to purchase accounting adjustments for acquisitions.

Other intangible assets were comprised of:

CostAccumulated amortizationNet book value
Assets subject to amortization:
Customer related intangibles$7,532.0$(2,108.0)$5,424.0
Unpatented technology906.4(431.8)474.6
Software149.5(122.4)27.1
Patents and other protective rights9.6(2.1)7.5
Trade names12.8(6.1)6.7
Assets not subject to amortization:
Trade names648.6—648.6
Balances at December 31, 2021$9,258.9$(2,670.4)$6,588.5
Assets subject to amortization:
Customer related intangibles$7,527.0$(2,205.3)$5,321.7
Unpatented technology893.6(445.6)448.0
Software149.4(125.2)24.2
Patents and other protective rights9.6(2.1)7.5
Trade names16.3(7.0)9.3
Assets not subject to amortization:
Trade names643.4—643.4
Balances at March 31, 2022$9,239.3$(2,785.2)$6,454.1

Amortization expense of other intangible assets was $145.8 and $145.1 during the three months ended March 31, 2022 and 2021, respectively.

An evaluation of the carrying value of goodwill and indefinite-lived intangibles is required to be performed on an annual basis and on an interim basis if an event occurs or circumstances change that would more likely than not reduce the fair value of a reporting unit below its carrying value. There have been no events or changes in circumstances which indicate an interim impairment review is required in 2022. The Company will perform the annual analysis during the fourth quarter of 2022.

9. Fair Value of Financial Instruments and Debt

Roper’s debt at March 31, 2022 included $7,500 of fixed-rate senior notes with the following fair values:

$500 3.125% senior notes due 2022503
$300 0.450% senior notes due 2022299
$700 3.650% senior notes due 2023710
$500 2.350% senior notes due 2024493
$300 3.850% senior notes due 2025305
$700 1.000% senior notes due 2025650
$700 3.800% senior notes due 2026717
$700 1.400% senior notes due 2027635
$800 4.200% senior notes due 2028831
$700 2.950% senior notes due 2029675
$600 2.000% senior notes due 2030534
$1,000 1.750% senior notes due 2031864

The fair values of the senior notes are based on the trading prices of each series of notes, which the Company has determined to be Level 2 in the FASB fair value hierarchy.

10. Contingencies

Roper, in the ordinary course of business, is party to various pending or threatened legal actions, including product liability, intellectual property, data privacy and employment practices that, in general, are of a nature consistent with those over the past several years. After analyzing the Company’s contingent liabilities on a gross basis and, based upon past experience with resolution of such legal claims and the availability and limits of the primary, excess, and umbrella liability insurance coverages with respect to pending claims, management believes that adequate provision has been made to cover any potential liability not covered by insurance, and that the ultimate liability, if any, arising from these actions should not have a material adverse effect on Roper’s consolidated financial position, results of operations or cash flows. However, no assurances can be given in this regard.

Roper’s subsidiary, Vertafore, Inc., was named in three putative class actions, two in the U.S. District Court for the Southern District of Texas (Allen, et al. v. Vertafore, Inc., Case 4:20-cv-4139, filed December 4, 2020) and Masciotra, et al. v. Vertafore, Inc., (originally filed on December 8, 2020 as Case 1:20-cv-03603 in the U.S. District Court for the District of Colorado and subsequently transferred), and one in the U.S. District Court for the Northern District of Texas (Mulvey, et al. v. Vertafore, Inc., Case 3:21-cv-00213-E, filed January 31, 2021). In July 2021, the court granted Vertafore’s motion to dismiss the Allen Case. In March 2022, the U.S. Fifth Circuit Court of Appeals affirmed the lower court’s dismissal of the Allen case. In July 2021, the plaintiff in the Masciotra case voluntarily dismissed his action without prejudice. The Allen case and the Mulvey case each purport to represent approximately 27.7 million individuals who held Texas driver’s licenses prior to February 2019. In November 2020, Vertafore announced that as a result of human error, three data files were inadvertently stored in an unsecured external storage service that appears to have been accessed without authorization. The files, which included driver information for licenses issued before February 2019, contained Texas driver license numbers, as well as names, dates of birth, addresses and vehicle registration histories. The files did not contain any Social Security numbers or financial account information. These cases seek recovery under the Driver’s Privacy Protection Act, 18 U.S.C. § 2721. In addition, Roper was advised that the Texas Attorney General is investigating the data event.

Roper’s subsidiary, Verathon, Inc. (“Verathon”), is defending a patent infringement action pending in the United States District Court for the Western District of Washington (Berall v. Verathon, Inc., Case No. 2:2021mc00043). Plaintiff claims that video laryngoscopes and certain accessories sold by Verathon from approximately 2006 through 2016 infringe U.S. Patent 5,827,178 (the “‘178 Patent”). The complaint seeks an unspecified amount of damages, enhanced damages, attorneys’ fees, costs, and pre-

and post-judgment interest. Verathon contends that the products at issue do not infringe the ‘178 Patent and that the ‘178 Patent is invalid. Verathon is vigorously defending the matter.

Roper or our subsidiaries have been named defendants along with numerous industrial companies in asbestos-related litigation claims in certain U.S. states. To date, no significant resources have been required by Roper to respond to asbestos claims. In the first quarter of 2022, Roper completed a transaction in which it transferred the remainder of our exposure for asbestos claims to a third party. In connection with this transaction, Roper incurred a one-time charge of $4.1, which is recorded as a component of “Other income (expense), net” within the Condensed Consolidated Statements of Earnings.

11. Business Segments

The following table presents selected financial information by reportable segment:

Three months ended March 31,
20222021Change %
Net revenues:
Application Software$631.5$576.69.5%
Network Software & Systems368.7314.217.3%
Measurement & Analytical Solutions392.4369.66.2%
Process Technologies134.0115.715.8%
Total$1,526.6$1,376.110.9%
Gross profit:
Application Software$437.8$398.79.8%
Network Software & Systems302.4256.417.9%
Measurement & Analytical Solutions217.6218.2(0.3)%
Process Technologies72.362.715.3%
Total$1,030.1$936.010.1%
Operating profit*:
Application Software$173.8$153.713.1%
Network Software & Systems145.4114.127.4%
Measurement & Analytical Solutions115.9121.5(4.6)%
Process Technologies41.835.119.1%
Total$476.9$424.412.4%
Long-lived assets:
Application Software$135.8$126.77.2%
Network Software & Systems28.527.82.5%
Measurement & Analytical Solutions32.533.9(4.1)%
Process Technologies13.318.3(27.3)%
Total$210.1$206.71.6%

*Segment operating profit is before unallocated corporate general and administrative expenses. These expenses were $55.8 and $49.8 for the three months ended March 31, 2022 and 2021, respectively.

12. Revenues from Contracts

Disaggregated Revenue - We disaggregate our revenues into two categories: (i) software and related services; and (ii) engineered products and related services. Software and related services revenues are primarily derived from our Application Software and Network Software & Systems reportable segments. Engineered products and related services revenues are derived from all of our reportable segments except Application Software and comprise substantially all of the revenues generated in our Measurement & Analytical Solutions and Process Technologies reportable segments. See details in the table below.

Three Months Ended March 31,
20222021
Software and related services$970.0$864.5
Engineered products and related services556.6511.6
Net revenues$1,526.6$1,376.1

Remaining performance obligations - Remaining performance obligations represent the transaction price of firm orders for which work has not been performed and excludes unexercised contract options. As of March 31, 2022, the aggregate amount of the transaction price allocated to remaining performance obligations was $4,000.3. We expect to recognize revenue of $2,718.0, or approximately 68% of our remaining performance obligations over the next 12 months (“Backlog”), with the remainder to be recognized thereafter.

Contract balances

Balance Sheet AccountMarch 31, 2022December 31, 2021Change
Unbilled receivables$110.0$95.3$14.7
Deferred revenue - current(1,120.3)(1,130.2)9.9
Deferred revenue - non-current (1)(111.5)(75.3)(36.2)
Net contract assets/(liabilities)$(1,121.8)$(1,110.2)$(11.6)

(1) The non-current portion of deferred revenue is included in “Other liabilities” in our Condensed Consolidated Balance Sheets.

The change in our net contract assets/(liabilities) from December 31, 2021 to March 31, 2022 was due primarily to the timing of payments and invoicing relating to Software-as-a-Service (“SaaS”) and post contract support (“PCS”) renewals, partially offset by the increase in unbilled receivables due to the timing of invoicing primarily related to software milestone billings associated with multi-year term license renewals and software implementations.

Most of the Company’s project-based contracts where the input method of revenue recognition is utilized are billed as work progresses in accordance with the contract terms and conditions, either at periodic intervals or upon achievement of certain milestones. Often this results in unbilled receivables where billing occurs after revenue recognition. The Company records deferred revenue when cash payments are received or due in advance of the Company’s performance relating primarily to SaaS and PCS renewals. Revenue recognized from the deferred revenue balance on December 31, 2021 and 2020 was $495.7 and $450.9 for the three months ended March 31, 2022 and 2021, respectively.

In order to determine revenues recognized in the period, we allocate revenue to the individual deferred revenue balance outstanding at the beginning of the year until the revenue exceeds that balance.

The current and non-current portions of deferred commissions are included in “Other current assets” and “Other assets,” respectively, in our Condensed Consolidated Balance Sheets. At March 31, 2022 and December 31, 2021, we had $58.3 and $56.7 of deferred commissions, respectively.

Previous: Cover and table of contents · Next: Item 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS